Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis

Vaccine

Volumn 22, Issue 9-10, 2004, Pages 1320-1326

  Armijos, R X ^a,b   Weigel, M M ^a   Calvopina, M ^b   Hidalgo, A ^b   Cevallos, W ^b   Correa, J ^b  

^a UNIVERSITY OF TEXAS AT EL PASO   (United States)

^b UNIVERSIDAD CENTRAL DEL ECUADOR   (Ecuador)

Author keywords

Ecuador; Leishmanin skin test; Leishvaccin

Indexed keywords

BCG VACCINE; LEISHMANIA VACCINE; PLACEBO;

ADOLESCENT; ADULT; ARTICLE; AUTOCLAVE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HUMAN; IMMUNOGENICITY; INCIDENCE; INJECTION PAIN; LEISHMANIA; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DEFECT; SKIN LEISHMANIASIS; SKIN MANIFESTATION; SKIN TEST; SKIN ULCER;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BCG VACCINE; CHILD; ECUADOR; FEMALE; FOLLOW-UP STUDIES; HEAT; HUMANS; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; MALE; PROTOZOAN VACCINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN TESTS; STERILIZATION; TREATMENT OUTCOME; VACCINATION;

EID: 1542360794     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.06.002     Document Type: Article

References (31)

1. World Health Organization. Control of the Leishmaniasis. Technical Report Series #793. Geneva: WHO; 1990.
2. Pan American Health Organization. Leishmaniasis in the Americas. Epidemiol Bull 1994;15:8-13.
3. Grimaldi G. Jr., Tesh R.B. Leishmaniases of the New World: current concepts and implications for future research. Clin. Microbiol. Rev. 6(3):1993;230-250.
4. Chulay J.D., Spencer H.C., Muganbi M. Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony. Am. J. Trop. Med. Hyg. 34:1985;702-709.
5. Berman J.D. Chemotherapy for leishmaniasis: biochemical mechanisms. Rev. Inf. Dis. 10:1988;560-586.
6. Berman J.D., Melby P.C., Neva F.A. Concentration of Pentostam in human breast milk. Trans. R. Soc. Trop. Med. Hyg. 83(6):1989;784-785.
7. Weigel M.M., Armijos R.X., Racines J.et al. Cutaneous leishmaniasis in subtropical Ecuador: popular perceptions, knowledge, and treatment. Bull. Pan. Am. Health Organ. 28(2):1994;144-152.
8. Weigel M.M., Armijos R.X. The traditional and conventional medical treatment of cutaneous leishmaniasis in rural Ecuador. Pan. Am. J. Pub. Health. 10(6):2001;395-403.
9. Armijos R.X., Weigel M.M., Aviles H.et al. Field trial of a vaccine against New World cutaneous leishmaniasis in at-risk child population: safety, immunogenecity, and efficacy during the first 12 months of follow-up. J. Infect. Dis. 177:1998;1352-1357.
10. Moddaber F. Vaccines against leishmaniasis. Trop. Med. Parasitol. 89(Suppl. 1):1995;83-88.
11. Mayrink W., Antunes C.M.F., Costa C.A.et al. Further trials of a vaccine against American cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 80:1986;1001.
12. Antunes C.M.F., Mayrink W., Magalhaes P.A.et al. Controlled field trial of a vaccine against New World cutaneous leishmaniasis. Int. J. Epidemiol. 15:1986;572-580.
13. Mayrink W., Williams P., Costa C.A.et al. An experimental vaccine against American dermal leishmaniasis: experience in the State of Spirito Santo, Brazil. Ann. Trop. Med. Parasitol. 79:1985;259-269.
14. UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. Tropical disease research: progress 1995-1996. In: Thirteenth Programme Report of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases; 1997.
15. ® (Biobras Pharmaceutical Company) in a non-endemic Ecuadorian population: final technical report to the Special Programme for Research and Training in Tropical Diseases (TDR)/UNDP/WB/WHO) #TDR950174; 1998.
16. Mendonca S.C.F., De Luca P.M., Mayrink W.et al. Characterizationof the cell-mediated immune response induced by a vaccine against American tegumentary leishmaniasis in humans. Mem. Inst. Oswaldo. Cruz. 88(suppl.I):1993;46.
17. Marzochi K.B., Marzochi M.A., Silva A.F.et al. Phase I study of an inactivated vaccine against American cutaneous tegumentary in normal volunteers in Brazil. Men Inst. Oswaldo. Cruz. 93:1998;205-212.
18. Velez I.D., Agudelo D.S., Arbelaez M.P.et al. Safety and immunogenicity of a killed Leishmania (L) amazonensis vaccine against cutaneous leishmaniasis in Colombia: a randomized controlled trial. Trans. R. Soc. Trop. Med. Hyg. 94:2000;698-703.
19. De Luca P.M., Mayrink W., Alves C.R.et al. Evaluation of stability and immunogenecity of autoclaved and nonautoclaved preparation of a vaccine against American tegumentary leishmaniasis. Vaccine. 17:1999;1179-1185.
20. De Luca P.M., Mayrink W., Pinto J.et al. A randomized double-blind placebo-controlled trial to evaluate the immunogenicity of a candidate vaccine against American cutaneous leishmaniasis. Acta Trop. 80:2001;251-260.
21. Armijos R.X., Weigel M.M., Izurieta R.et al. Epidemiology of cutaneous leishmaniasis in an endemic area of subtropical Ecuador. Trop. Med. Int. Health. 2(2):1997;140-152.
22. Armijos R.X., Chico M.E., Cruz M.E.et al. Human cutaneous leishmaniasis in Ecuador: characterization of parasites by isoenzyme electrophoresis. Am. J. Trop. Med. Hyg. 45(5):1990;424-428.
23. Armijos R.X., Rioux J.A., Racines J.et al. Analyse chimiotaxonomique de vingt-deux souches de Leishmania isolees au Nord-Ouest de l'Equateur. Parasite. 2:1995;301-305.
24. Mendonca S.C., De Luca P.M., Mayrink W.et al. Caracterization of human T lymphocyte - mediated immune response by a vaccine against American tegumentary leishmaniasis. Am. J. Trop. Med. Hyg. 53:1995;195-201.
25. Momeni A.Z., Jalayer T., Emamjomeh M.et al. A randomized, double-blind controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine. 17:1998;466-472.
26. Laison R., Shaw J.J. Leishmaniasis in Brazil. XII. Observation on cross-immunity in monkeys and man infected with Leishmania mexicana mexicana, L.m. amazonensis, Leishmania braziliensis braziliensis, L.b. guyanensis and L.b. panamensis. Trans. R. Soc. Trop. Med. Hyg. 80:1977;29-35.
27. Saravia N.G., Weigle K., Segura I.et al. Recurrent lesions in humans Leishmania braziliensis infection-reactivation or reinfection? Lancet. 336:1990;398-402.
28. Victoir K., Bañuls A.L., Arevalo J.et al. The gp-63 gene locus a target for genetic characterization of Leishmania belonging to subgenus. Viannia. Parasitol. 117:1998;1-13.
29. Guerbouj S., Victoir K., Guizani I.et al. Gp63 gene polymorphysm and population structure of Leishmania donovani complex: influence of the host selection pressure? Parasitology. 122:2001;25-35.
30. Turco S.J., Gerald F., Beverley S.M. Is lipophosphoglycan a virulent factor? A surprising diversity between Leishmania species. Trends Parasitol. 17:2001;223-226.
31. Hernandez-Montes O., Monroy-Ostria A., McCann S.et al. Identification of Mexican Leishmania species by analysis of PCR amplified DNA. Acta Trop. 71:1998;139-152.